An Overview of Mirdametinib: Drug Profile, Mechanism, Clinical efficacy, and Safety study in the Management of NF1-Associated Tumors

Neurofibromatosis type I (NF-1) is an autosomal dominant genetic disorder, typically accompanied by plexiform neurofibroma. NF1 mutations cause aberrant activation of the RAS/RAF/MEK/ERK signaling pathway, which results in unchecked tumor growth. While recent research has investigated a number of treatments, such as mitogen-activated protein kinase kinase (MEK) inhibitors, which target the RAS/mitogen-activated protein kinase (MAPK) pathway, a major driver of NF1-associated tumorigenesis, surgical intervention for plexiform neurofibromas is reserved for high-risk cases. The US Food and Drug Administration (FDA) recently approved mirdametinib (GOMEKLI), an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) developed by Spring Works Therapeutics, for the treatment of adult and pediatric NF-1 patients with symptomatic, inoperable PNs who are two years of age or older. The EU is now reviewing the EU, mirdametinib. Clinical trials for the therapy of juvenile low-grade gliomas are now underway for mirdametinib. This article describes the stages of mirdametinib's development that resulted in its initial approval. This article summarizes the development of NF1, the role of MEK inhibition, and the discovery of mirdametinib as a treatment for NF1-associated plexiform neurofibromas. PubMed searches were used to locate pertinent information using keywords related to NF1, plexiform neurofibromas, MEK inhibition, and mirdametinib. This contained details about mirdametinib's pharmacologic properties, safety profile, clinical efficacy, and comparability with other MEK inhibitors.